aidsmap news story
More people with HIV can be considered for two-drug treatment either with dolutegravir/lamivudine or injectable cabotegravir/rilpivirine, according to updated European AIDS Clinical Society (EACS) guidelines presented at HIV Glasgow 2026.
The new guidelines open up treatment with dolutegravir/lamivudine (Dovato) to people with high viral load, and people with suppressed viral load who have a history of resistance to lamivudine. Pregnant women and children over the age of two should also be able to take dolutegravir/lamivudine if they have suppressed viral load, the new guidelines recommend.
Read thew full news story here.
View all aidsmap reports from HIV Glasgow 2026
SEE ALSO:
- [HIV Glasgow 2026] Life4me+ | Three key updates in HIV treatment: EACS guidelines
View all Life4me+ reports from HIV Glasgow 2026
Source : aidsmap
Related HIV and Co-Infections News
-
[HIV Glasgow 2026] aidsmap | Dolutegravir resistance has not risen in Lesotho cohort
-
[HIV Glasgow 2026] Infectious Disease Special Edition | Bixlenvo maintains viral suppression even among patients with preexisting resistance mutations
-
[HIV Glasgow 2026] aidsmap/Life4me+ | A pair of antibodies keeps HIV undetectable – but who would benefit most?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.